Clinical Trials
18 trialsNCT03574649 2025-02-21
QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer
ImmunityBio, Inc.
Phase 2 Withdrawn
NCT06370871 2024-07-17
Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma
Boehringer Ingelheim
Phase 3 Withdrawn
NCT04151563 2023-12-19
CheckMate 79X
Bristol-Myers Squibb
Phase 1/2 Withdrawn
NCT03770299 2022-03-24
CheckMate 9TN
Bristol-Myers Squibb
Phase 2 Withdrawn
NCT04430933 2021-08-18
A Safety and Tolerability Study of NC318 in Combination With Chemotherapy for Subjects With Advanced or Metastatic NSCLC
NextCure, Inc.
Phase 1/2 Withdrawn
NCT04260360 2020-08-04
Trial of NanoDoce Intratumoral Injection in Renal Cell Carcinoma
NanOlogy, LLC
Phase 1 Withdrawn
NCT02831491 2020-06-09
A Study of Ramucirumab (LY3009806) in Combination With Weekly Docetaxel in Participants With Stage IV Non-Small Cell Lung Cancer
Eli Lilly and Company
Phase 2 Withdrawn
NCT03811418 2019-11-26
ATTILA
iOMEDICO AG
Phase 3 Withdrawn
NCT02651610 2017-07-11
Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer
Peregrine Pharmaceuticals
Phase 2/3 Withdrawn
NCT00774241 2016-11-02
PRIMADOS Study:A Study of Avastin (Bevacizumab) Plus Docetaxel for First Line Treatment of Patients With Metastatic Breast Cancer
Hoffmann-La Roche
Phase 4 Withdrawn
NCT00964704 2016-11-02
A Study of Herceptin (Trastuzumab) in Combination With Avastin (Bevacizumab) and Sequential Xeloda (Capecitabine) or Docetaxel in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer
Hoffmann-La Roche
Phase 2 Withdrawn
NCT01245543 2015-11-02
Safety Study for Intravenous (IV) AC480 (AC480IV) to Treat Advanced Solid Tumors
Daiichi Sankyo
Phase 1 Withdrawn
NCT00697060 2015-06-24
A Safety and Efficacy Trial of Amplimexon Plus Taxotere in Metastatic Non-Small Cell Lung Cancer
AmpliMed Corporation
Phase 2 Withdrawn
NCT00471159 2015-05-04
A Study Of Docetaxel Or Docetaxel Plus PF-3512676 To Treat Patients With Advanced Breast Cancer.
Pfizer
Phase 2 Withdrawn
NCT00678626 2015-05-04
Phase 2 Trial Of CP-751,871 And Docetaxel In Advanced Breast Cancer
Pfizer
Phase 2 Withdrawn
NCT01938456 2014-07-28
Safety and Tolerability of Trametinib in Combination With Docetaxel in Japanese Subjects With Non-small Cell Lung Cancer
GlaxoSmithKline
Phase 1 Withdrawn
NCT01137994 2013-03-13
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer
GlaxoSmithKline
Phase 2 Withdrawn
NCT00386555 2012-08-09
A Phase 2 Study in Patients With Advanced Non-Small Cell Lung Cancer Using New Agents With and Without Docetaxel.
Arog Pharmaceuticals, Inc.
Phase 2 Withdrawn